2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Immune Mechanism, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult
PAPER

5834 Phenotypic and genomic markers of aging identify cardiovascular risk and mortality after transplantation for multiple myeloma

Rusha Bhandari, MD,MS, Sitong Chen, MPH2, Alysia Bosworth, BA3, Scott R Goldsmith, MD4, Amrita Krishnan, MD, FACP5, Lanie Lindenfeld6, Kameron Mortazavi7, Michael Rosenzweig, MD8, Molly E. Thornock, BSN, RN, CPHON9, Megan Vuong10, F. Lennie Wong, PhD11, Stephen J. Forman, MD12, Saro H Armenian, MD, MPH13, June-Wha Rhee, MD14
1 City of Hope, Duarte, United States
2 City of Hope, Duarte, United States
3 City of Hope, Duarte, United States
4 City of Hope, Duarte, United States
5 City of Hope, Irvine, United States
6 City of Hope, Duarte, United States
7 City of Hope, Duarte, United States
8 City of Hope, Duarte, United States
9 City of Hope, Duarte, United States
10 City of Hope, Duarte, United States
11 City of Hope, Duarte, United States
12 City of Hope, Duarte, United States
13 City of Hope, Duarte, United States
14 City of Hope, Duarte, United States

Introduction: Autologous hematopoietic cell transplantation (HCT) remains an integral component of treatment for eligible patients with multiple myeloma (MM). Despite improvements in overall outcomes, cardiovascular disease (CVD) and premature mortality have emerged as important threats to long-term health after HCT. These outcomes reflect the combined effects of malignancy, treatment exposures, comorbidities, and lifestyle factors, yet their occurrence varies considerably among patients of similar chronologic age. This variability may reflect differences in biologic aging that are not captured by conventional clinical risk factors. We previously demonstrated that clonal hematopoiesis (CH), a genomic marker of aging, is independently associated with CVD and mortality after HCT (JAMA Cardiol 2024). However, biologic aging is multidimensional, and genomic testing is not routinely available in clinical practice. Phenotypic age acceleration (PAA), calculated from routinely collected laboratory measures, has been associated with CVD and premature mortality in non-oncology populations, but its prognostic relevance in MM is unknown. We evaluated the association between PAA, CVD, and mortality among patients who underwent autologous HCT for MM and examined whether PAA provided complementary risk information to CH.

Methods: This was a retrospective cohort study of patients with MM who underwent autologous HCT between 2010 and 2016 at City of Hope. Phenotypic age was calculated using pre-HCT serum albumin, creatinine, glucose, total white blood cell count, lymphocyte percent, mean corpuscular volume, red cell distribution width, alkaline phosphatase, and chronologic age. PAA was calculated as the residuals from regressing phenotypic age on chronologic age; positive values indicated an older biologic age than expected. Data on post-HCT CVD (including cardiomyopathy, stroke, and coronary artery disease) were abstracted from medical records. Patients with a history of CVD before HCT (n=141) were excluded from the CVD analysis. Cumulative CVD incidence was estimated across four categories representing phenotypic and genomic aging: 1) PAA ≤0/no CH; 2) PAA >0/no CH; 3) PAA ≤0/CH; and 4) PAA >0/CH. Multivariable Fine–Gray regression accounting for death as a competing risk estimated associations with incident CVD. Cox regression estimated associations with all-cause mortality. Models were adjusted for chronologic age, sex, HCT-Comorbidity Index, and CH status, as applicable.

Results: The study included 985 patients (mean age at HCT, 59 years [SD 8.2], 53% male); 19% had CH. Median duration of follow-up was 5.0 years (range 0-8). A total of 96 patients developed CVD, and 415 died. After multivariable adjustment, each 1-year increase in PAA was independently associated with a higher incidence of CVD (subdistribution hazard ratio [sHR] 1.02, 95% CI 1.00-1.04; p=0.02). The 8-year cumulative incidence of CVD demonstrated a stepwise gradient across the combined PAA/CH categories: PAA ≤0/no CH (n=455): 9.3% [95% CI 6.6-12.4%]; PAA >0/no CH (n=235): 13.8% [95% CI 9.4-19.1%]; PAA ≤0/CH (n=103): 17.3% [95% CI 9.7-26.6%]; PAA >0/CH (n=51): 31.8% [95% CI 19.4-44.9%]). Compared with PAA ≤0/no CH, the PAA >0/CH phenotype was associated with a greater than 3-fold risk of CVD (sHR 3.3, 95% CI 1.8-6.1; p<0.01). PAA also remained independently associated with all-cause mortality after adjustment for CH and other covariates (HR per 1-year increase: 1.01, 95% CI 1.00-1.02; p=0.03).

Conclusion: Among patients with MM undergoing autologous HCT, accelerated phenotypic aging was independently associated with CVD and all-cause mortality, providing risk information complementary to CH. Nearly one-third of patients with both PAA and CH developed CVD, compared with fewer than one in ten patients with neither marker, supporting the potential value of integrating phenotypic and genomic measures of aging in risk assessments. Because PAA uses laboratory values routinely collected in clinical care, it offers a readily scalable approach to refining pre-HCT risk stratification and targeting post-HCT cardiovascular surveillance. These findings may inform risk-adapted prevention and surveillance strategies to reduce CVD and improve long-term survival in this vulnerable population.

Rusha Bhandari, MD,MS: No relevant conflicts of interest to declare.